A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Summary

This 3-part study will explore the safety and tolerability of GLWL-01 in overweight/obese healthy participants after single doses (in Part A), and in participants with type 2 diabetes mellitus after multiple doses during a 28-day period (Parts B and C).

Timeline

Start

2015-03

Primary completion

2016-11-09

Completion

2016-11-09

Outcome

Outcome not reported

Stopped: “Insufficient efficacy for this indication. The study stopped after Part B.”

Drugs

Indications